Efaroxan

Efaroxan is a potent, selective and orally active α2-adrenoceptor antagonist, with antidiabetic activity. Efaroxan is a selective I1-Imidazoline receptor antagonist. Efaroxan can be used for the research of cardiovascular disease[1][2][3].

89197-32-0

12352005

Adrenergic Receptor; Imidazoline Receptor

GPCR/G Protein; Neuronal Signaling

Cardiovascular Disease; Metabolic Disease

CCC1(C2=NCCN2)OC3=CC=CC=C3C1

C13H16N2O

216.28

[1]Berridge TL, et al. Selectivity profile of the alpha 2-adrenoceptor antagonist efaroxan in relation to plasma glucose and insulin levels in the rat. Eur J Pharmacol. 1992 Mar 24;213 (2) :205-12. |[2]A O Abdel-Zaher, et al. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists. Pharmacol Res. 2001 Nov;44 (5) :397-409.|[3]T L Berridge, et al. Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats. Eur J Pharmacol. 1992 Mar 24;213 (2) :213-8.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B1416/

Reference compound1

No Development Reported